
TherapeuticsMD TXMD
$ 1.9
1.06%
Country |
|
IPO year |
- |
Industry |
Drug manufacturers |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
11.6 M |
Market Cap[1] |
$ 22 M |
EBITDA (LTM) |
$ -4.01 M |
P/E (LTM) |
-44.2 |
P/S (LTM) |
8.460453 |
EPS (LTM) |
-0.05 |
Other stocks of industry "Drug manufacturers"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
Perrigo Company plc
PRGO
|
$ 15.91 | -1.64 % | $ 2.2 B | NYSE | ||
|
Cumberland Pharmaceuticals
CPIX
|
$ 8.17 | 2.64 % | $ 121 M | Nasdaq Global Select Market | ||
|
Evolus
EOLS
|
$ 7.4 | 0.41 % | $ 477 M | Nasdaq Global Market | ||
|
Tricida
TCDA
|
- | - | $ 3.25 M | Nasdaq Global Select Market,SPB | ||
|
Avadel Pharmaceuticals plc
AVDL
|
- | - | $ 2.06 B | Nasdaq Global Select Market | ||
|
DURECT Corporation
DRRX
|
- | - | $ 50.1 M | Nasdaq Capital Market | ||
|
Aerie Pharmaceuticals
AERI
|
- | - | $ 754 M | Nasdaq Global Market,SPB | ||
|
Endo International plc
ENDP
|
- | - | $ 28.9 M | Nasdaq Global Select Market,SPB | ||
|
Radius Health
RDUS
|
- | - | $ 1.42 B | Nasdaq Global Market | ||
|
Recro Pharma
REPH
|
- | -4.76 % | $ 65.3 M | Nasdaq Global Select Market | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
- | 0.86 % | $ 117 M | Nasdaq Capital Market | ||
|
Agile Therapeutics
AGRX
|
- | 10.11 % | $ 58.2 M | Nasdaq Capital Market | ||
|
Evoke Pharma
EVOK
|
- | - | $ 36.6 M | Nasdaq Capital Market | ||
|
Alimera Sciences
ALIM
|
- | - | $ 142 M | Nasdaq Global Market | ||
|
PLx Pharma
PLXP
|
- | -27.8 % | $ 2.56 M | Nasdaq Capital Market | ||
|
Athenex
ATNX
|
- | -23.39 % | $ 1.76 M | Nasdaq Global Select Market | ||
|
Lannett Company
LCI
|
- | 1.15 % | $ 7.11 M | NYSE | ||
|
Zynerba Pharmaceuticals
ZYNE
|
- | - | $ 55.5 M | Nasdaq Global Market,SPB | ||
|
Aurora Cannabis
ACB
|
$ 3.96 | -0.25 % | $ 217 M | NYSE | ||
|
Catalent
CTLT
|
- | - | $ 11.5 B | NYSE,SPB | ||
|
Eagle Pharmaceuticals
EGRX
|
- | -39.89 % | $ 27.7 M | Nasdaq Global Market,SPB | ||
|
OptiNose
OPTN
|
- | - | $ 1.08 B | Nasdaq Global Select Market | ||
|
Emergent BioSolutions
EBS
|
$ 6.2 | -1.43 % | $ 332 M | NYSE,SPB | ||
|
PetIQ
PETQ
|
- | 1.64 % | $ 400 M | Nasdaq Global Select Market,SPB | ||
|
Pacira BioSciences
PCRX
|
$ 36.33 | -0.14 % | $ 1.62 B | Nasdaq Global Select Market,SPB | ||
|
Rockwell Medical
RMTI
|
$ 7.08 | -2.07 % | $ 255 M | Nasdaq Global Market | ||
|
Solid Biosciences
SLDB
|
$ 6.41 | 0.16 % | $ 561 M | Nasdaq Global Select Market,SPB | ||
|
Tilray
TLRY
|
$ 2.92 | -3.63 % | $ 327 M | Nasdaq Global Select Market | ||
|
Veru
VERU
|
$ 2.3 | -3.36 % | $ 33.7 M | Nasdaq Capital Market | ||
|
Viatris
VTRS
|
$ 18.45 | -1.07 % | $ 21.2 B | Nasdaq Global Select Market,SPB | ||
|
Harrow Health
HROW
|
$ 28.24 | 0.61 % | $ 1.04 B | Nasdaq Global Market | ||
|
Canopy Growth Corporation
CGC
|
$ 0.67 | -6.67 % | $ 200 M | Nasdaq Global Select Market | ||
|
Organogenesis Holdings
ORGO
|
$ 0.99 | -2.81 % | $ 125 M | Nasdaq Capital Market | ||
|
SCYNEXIS
SCYX
|
$ 3.79 | -0.39 % | $ 189 M | Nasdaq Global Select Market | ||
|
Sundial Growers
SNDL
|
$ 1.28 | 0.39 % | $ 330 M | Nasdaq Global Select Market | ||
|
Sonoma Pharmaceuticals
SNOA
|
$ 1.14 | -0.87 % | $ 1.92 M | Nasdaq Capital Market | ||
|
OrganiGram Holdings
OGI
|
$ 0.94 | 0.38 % | $ 89.6 M | Nasdaq Global Select Market | ||
|
cbdMD
YCBD
|
$ 0.38 | -2.14 % | $ 1.53 M | NYSE American | ||
|
Bausch Health Companies
BHC
|
$ 6.45 | 0.55 % | $ 2.39 B | NYSE | ||
|
Cronos Group
CRON
|
$ 3.39 | 3.35 % | $ 1.3 B | Nasdaq Global Market | ||
|
China Pharma Holdings
CPHI
|
$ 0.7 | -3.78 % | $ 3 M | NYSE American | ||
|
Relmada Therapeutics
RLMD
|
$ 3.21 | -4.46 % | $ 127 M | Nasdaq Global Select Market,SPB | ||
|
HEXO Corp.
HEXO
|
- | 2.45 % | $ 38.1 M | NYSE | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
- | -0.1 % | $ 2.03 B | Nasdaq Global Select Market | ||
|
AcelRx Pharmaceuticals
ACRX
|
- | 7.5 % | $ 6.35 M | Nasdaq Global Market | ||
|
Assertio Holdings
ASRT
|
- | - | $ 150 M | Nasdaq Capital Market | ||
|
Jupiter Wellness
JUPW
|
- | - | $ 33.6 M | Nasdaq Global Select Market | ||
|
Neoleukin Therapeutics
NLTX
|
- | - | $ 193 M | Nasdaq Global Select Market | ||
|
ProPhase Labs
PRPH
|
- | - | $ 5.07 M | Nasdaq Capital Market |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.